Ruxolitinib is a type of medication known as a Janus kinase (JAK) inhibitor. It works by blocking the activity of two enzymes, JAK1 and JAK2, which are involved in the signaling pathways that control blood cell production and immune responses.

In certain blood cancers, such as myeloproliferative neoplasms (which include myelofibrosis and polycythemia vera), these pathways are overactive, leading to abnormal growth of blood cells. By inhibiting JAK1 and JAK2, ruxolitinib helps to reduce the overproduction of blood cells and decrease inflammation. This can lead to a reduction in symptoms such as enlarged spleen, fatigue, and other disease-related issues. Ruxolitinib also helps regulate immune cell activity, which is important in conditions like graft-versus-host disease.

The effects of ruxolitinib are generally seen within weeks of starting treatment, but it is important to continue taking the medication as prescribed for the best results.

ruxolitinib

Common brand names

Approved use in